thumbnail image
broken image
broken image

seek and you will find

  • Home
  • Technology
  • Products 
    • Products Overview
    • SeekInCare
    • SeekInCure
    • SeekInClarity
    • OncoSeek
    • LeukoPrint
    • PanCanSeek
    • LungCanSeek
  • Publication 
    • Research
    • Others
  • Newsroom
  • Product & Service Inquiry
  • …  
    • Home
    • Technology
    • Products 
      • Products Overview
      • SeekInCare
      • SeekInCure
      • SeekInClarity
      • OncoSeek
      • LeukoPrint
      • PanCanSeek
      • LungCanSeek
    • Publication 
      • Research
      • Others
    • Newsroom
    • Product & Service Inquiry
broken image
broken image

seek and you will find

  • Home
  • Technology
  • Products 
    • Products Overview
    • SeekInCare
    • SeekInCure
    • SeekInClarity
    • OncoSeek
    • LeukoPrint
    • PanCanSeek
    • LungCanSeek
  • Publication 
    • Research
    • Others
  • Newsroom
  • Product & Service Inquiry
  • …  
    • Home
    • Technology
    • Products 
      • Products Overview
      • SeekInCare
      • SeekInCure
      • SeekInClarity
      • OncoSeek
      • LeukoPrint
      • PanCanSeek
      • LungCanSeek
    • Publication 
      • Research
      • Others
    • Newsroom
    • Product & Service Inquiry
broken image
  • LeukoPrint®

    Hematologic Malignancy Molecular Karyotyping Test

    broken image

    Current cytogenetic diagnostics for hematologic malignancies rely on karyotyping and FISH. Conventional karyotyping requires viable cells and has low resolution/sensitivity. While FISH is sensitive, it only assesses predetermined targets and misses novel aberrations.

    LeukoPrint® provides automated molecular karyotyping to efficiently detect genome-wide copy number aberration (CNA) and copy neutral loss of heterozygosity (CN-LOH). It addresses these gaps in traditional methods, reveals novel variants, and complements routine diagnostics to increase diagnostic yield.

    Molecular karyotyping

    Precision diagnosis

    Risk stratification

    Therapy guidance

    broken image
  • Advantages

    broken image

    No in vitro culture needed

    High sensitivity & reliability

    Automated analysis

    Professional report interpretation

  • An example of CNA profiling of LeukoPrint® reveals abnormal karyotype at molecular level

    broken image

    LeukoPrint® Karyotyping

  • Specifications

    ◉ Indicated subjects:Patients suspected or diagnosed with hematologic malignancies (MDS/AML/ALL/CLL/MM)

    ◉ Sample requirement:2-4ml bone marrow

    ◉ Result readout:CNA and CN-LOH

    ◉ Turnaround time (TAT):10 working days

  •  

    How it works

    broken image

    Customer order

    Customers can place orders through SeekIn official website or local agents

    broken image

    Blood-draw

    2-4ml bone marrow collected in EDTA tubes and ransport under refrigeration

    broken image

    Testing

    Detection by next generation sequencing (NGS) platform

    broken image

    Reporting

    The test results will be ready in about 10 workdays after your blood draw arrived at central lab

  • Please review the instructions to gain a better understanding of LeukoPrint® and assess whether it meets your needs.

    Download the Instructions

Navigation

Technology   

SeekInCare

SeeInCure

SeekInClarity

OncoSeek

Research

Contact Us

10320 Camino Santa Fe, Suite G

San Diego, CA 92121

United States

info@seekincancer.com

© 2024 SeekIn Inc.

All Rights Reserved.

Cookie Use
We use cookies to ensure a smooth browsing experience. By continuing we assume you accept the use of cookies.
Learn More